It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s Edoxaban Demonstrates Efficacy, Safety in AF Patients Undergoing Catheter Ablation
March 20, 2019
- Ono Files Multiple Myeloma Treatment Kyprolis for Once-Weekly Administration Regimen
March 20, 2019
- Servier, Oncodesign Join Forces to Develop Parkinson’s Disease Treatments
March 20, 2019
- NapaJen, Astellas Form Oligonucleotide Research Collaboration
March 19, 2019
- Ono Ties Up with AI Startup twoXAR on Drug Discovery
March 19, 2019
- 9 Month Cost-Effectiveness Analysis Possible If Companies Are Well-Prepared: Crecon Official
March 19, 2019
- Employee Sues Bayer Japan for Emotional Distress over Xarelto Scandal
March 19, 2019
- Hitachi Chemical Aspires to World’s No. 1 Regenerative Medicine CMO by Securing Bases in US, Europe through M&As
March 19, 2019
- Entrectinib Filed in Japan for ROS1 Lung Cancer: Chugai
March 18, 2019
- Alfresa Seeks to Expand Foothold in China via Tie-Up with 2nd Largest Drug Wholesaler
March 18, 2019
- Drug Makers, Wholesalers Establishing Supervisory Divisions as Detailing Guidelines Rollout Nears
March 15, 2019
- Synthetic Rubber Form of Rivastach/Exelon Patch Approved: Ono/Novartis
March 15, 2019
- Aricept Generics Earn Lewy Body Dementia Indications
March 14, 2019
- Fujifilm Going Full Throttle in CDMO Biz with Buyout of Biogen Unit
March 13, 2019
- Urief Authorized Generics Now Available: Daiichi Sankyo Espha
March 13, 2019
- FDA Accepts NDA for Insomnia Med Lemborexant, Target Date Set for Dec. 27
March 13, 2019
- Vadadustat Demonstrates Efficacy, Safety in 4 PIII Studies for Renal Anemia: Mitsubishi Tanabe
March 13, 2019
- Galderma Delivers in PIIb Atopic Dermatitis Study for Nemolizumab, Originated by Chugai
March 12, 2019
- Vimpat Dry Syrup Now Available: Daiichi Sankyo, UCB
March 12, 2019
- BMS, Ono Submit Additional Study Data on Orencia for Prevention of Structural Damage to Joints
March 12, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…